U.S. Infrastructure Stock News

IDEXX Laboratories has launched the Catalyst proBNP Test, the first dual-species in-clinic NT-proBNP cardiac assay for cats and dogs, extending its connected diagnostics portfolio and enabling real-time cardiac assessment on its nearly 80,000-strong Catalyst analyzer base. By opening access to an estimated US$4.00 billion global cardiac testing opportunity and embedding decision support into VetConnect PLUS, the new test could deepen IDEXX’s role in everyday veterinary cardiac care...

Recent share price context for Lakeland Financial Lakeland Financial (LKFN) has drawn investor attention after recent share price moves, with the stock closing at US$60.07 on 18 August 2026. Short term returns have been mixed over the past week and month. See our latest analysis for Lakeland Financial. The recent pullback in Lakeland Financial's 1 day share price return of 2.29% and 7 day share price return of 3.5% contrasts with a positive year to date share price return of 6.39% and a 3...

Lyntris (LYNX) has just completed a US$297.5 million IPO, offering 17,000,000 common shares at US$17.50 each in a sponsor backed deal. That pricing now anchors its early trading. See our latest analysis for Lyntris. Since listing at US$17.50, Lyntris has seen its share price fall 14.23% on a 1 day basis to US$15.01, signalling fading early momentum as investors reassess the sponsor backed IPO valuation. If the Lyntris IPO has you thinking about other potential opportunities in defense related...

Nike (NKE) is under pressure as its turnaround effort collides with weak digital demand, softer Greater China sales, and rising competition. Leadership changes and cautious sentiment now frame how investors read every new development. See our latest analysis for NIKE. Nike’s share price has bounced 2.47% over the past day and 1.33% over the past week, yet the 35.13% year to date share price decline and 44.69% fall in 1 year total shareholder return show momentum is still weak despite...

Aon (AON) is in focus after a cluster of leadership changes and a new product launch that together reshape how the company presents its risk and capital capabilities to clients and, by extension, to investors. See our latest analysis for Aon. These leadership changes and the launch of Sidecar X come as Aon trades at US$348.43, with a 90 day share price return of 7.47% but a 1 year total shareholder return that has declined 5.97%. This suggests that recent momentum contrasts with more subdued...

In mid-August 2026, Gates Industrial Corporation saw its shares react to weaker-than-expected July U.S. industrial production data reported by the Federal Reserve, which raised concerns about softer activity across key manufacturing end markets. This macro-driven shift highlights how sensitive Gates Industrial’s outlook can be to changes in broad U.S. industrial output rather than only company-specific news. We’ll now examine how worries about slower U.S. industrial production might...

Over the past six months, Vita Coco Company has delivered strong quarterly results and robust volume gains, with average quarterly volume up 15.2% over the last two years compared with peers. This consistently faster volume expansion versus competitors highlights Vita Coco’s growing brand strength and operational momentum in the coconut water category. We’ll now explore how Vita Coco’s outsized volume growth and recent performance may influence its existing investment narrative and risk...

RUM Group (RUM) has drawn fresh attention after issuing third quarter 2026 revenue guidance of US$87 million to US$93 million, the first full quarter that is expected to reflect its Quake AI integration. See our latest analysis for RUM Group. The share price has reacted strongly to these updates, with an approximate 43% 30 day share price return and a 31% year to date share price return. The 1 year total shareholder return of about 9% points to more modest longer term momentum. If RUM Group's...

Cullinan Therapeutics (CGEM) is back in focus after announcing that the global Phase 3 REZILIENT3 trial of zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion non small cell lung cancer met its primary endpoint. See our latest analysis for Cullinan Therapeutics. The Phase 3 REZILIENT3 update arrives after a strong run in Cullinan Therapeutics' stock, with a 1 month share price return of 28.69% and a year to date share price return of 122.53%. Over a longer horizon, the 1 year...

QuinStreet’s latest earnings and guidance draw investor focus QuinStreet (QNST) has moved into the spotlight after reporting quarterly and full year results that showed higher sales and net income, alongside new revenue guidance for fiscal 2027 that signals management confidence. See our latest analysis for QuinStreet. QuinStreet’s recent earnings announcement and acquisition commentary have been met with strong momentum, with a 30 day share price return of 23.01% and a 3 year total...

Taysha Gene Therapies recently reported second-quarter 2026 results showing a net loss of US$46.64 million and basic loss per share of US$0.13, while also completing patient dosing in pivotal TSHA-102 Rett syndrome trials that achieved a 100% responder rate in Part A by 12 months. Alongside this clinical progress, the company expanded its commercial manufacturing partnership with Catalent and secured US$230 million in financing, extending its cash runway into late 2028 and reinforcing its...

Earlier this month, Camden Property Trust filed an $802.865 million shelf registration to offer 7,250,000 common shares of beneficial interest for an ESOP-related program. This sizable ESOP-linked shelf suggests Camden is preparing to use equity more actively in employee ownership and compensation, with potential implications for its capital structure. We’ll now explore how this large ESOP-related equity shelf may affect Camden’s existing investment narrative built around Sun Belt...

Amcor (NYSE:AMCR) is back on investor radar after reporting fourth quarter sales of US$6.4b and net income of US$389m, alongside full year sales of US$23.5b and net income of US$1.1b. See our latest analysis for Amcor. The latest earnings release and dividend affirmation appear to have shifted sentiment toward Amcor. The stock’s recent 1 month share price return of 9.76% and 90 day share price return of 23.25% point to building momentum, while the 1 year total shareholder return of 17.60%...

Long term Treasury yields have swung from multi year highs to a sudden pause as the U.S. government plans to more than double bond buybacks, and that ripple hits everything from mortgages to life insurers and annuity providers. Capital is being pulled in many directions and investors risk sitting on the sidelines. This article walks through 3 stocks exposed to these rate moves and how they might be affected. The three stocks below are just a starting sample, and the full screen surfaced 11...

Recent coverage highlighted Healthcare Services Group’s strong operational efficiency, including solid receivables turnover, asset utilization, inventory management, and operating margins across its housekeeping, laundry, maintenance, and food service operations for healthcare facilities. The company’s very large average four-quarter earnings surprise of 57.3% has drawn attention to how its execution may be supporting profitability versus expectations. We’ll now examine how Healthcare...

Fed officials are once again talking tough on inflation, and that puts transaction driven banks and broker-dealers under a fresh spotlight. When rate expectations swing, cash sweep balances, trading activity, and client behavior can all shift in ways that matter for your portfolio. This article walks through three U.S. stocks exposed to this latest Fed debate, explaining how the recent news could influence investor sentiment, whether positively or negatively. The stocks covered in the article...

In recent days, Boston Beer Company has faced a unionization drive at its Sam Adams Brewery while continuing to contend with declining volumes and market share in core brands like Twisted Tea and Truly, alongside rising tariff-related cost pressures. At the same time, Angry Orchard’s Halloween tie-up with the Scream franchise highlights how Boston Beer is leaning on themed collaborations and limited-edition releases to support brand engagement amid broader industry headwinds. Next, we will...

In August 2026, GeneDx launched a nationwide online pathway that lets families of children with global developmental delay, intellectual disability, or epilepsy initiate clinician-guided exome testing directly from GeneDx.com, helping bypass long waits for in-person genetics appointments. This digital access model targets a large pool of underserved pediatric patients and aligns closely with updated American Academy of Pediatrics guidance that supports exome sequencing as a first-tier test,...

Candel Therapeutics, Inc. reported second-quarter 2026 results, with net loss widening to US$38.91 million and basic and diluted loss per share from continuing operations at US$0.52, while first-half 2026 net loss reached US$47.77 million compared with net income in the prior-year period. The sharp shift from profitability to loss over six months highlights a significant change in Candel Therapeutics’ operating profile that investors will scrutinize closely. We will now examine how this...

In August 2026, Charter Communications’ subsidiaries completed a large debt refinancing, exchanging multiple long-dated bonds for new 7.087% 2038 and 7.337% 2041 senior secured notes, while Spectrum and Optimum agreed to restore and expand carriage of NY1, News 12 and Spectrum News across key U.S. markets. By reshaping its debt profile and broadening distribution of its local news channels alongside expanded ad sales cooperation, Charter is aiming to improve financial flexibility and unlock...

Scholar Rock Holding (SRRK) is back in focus after its latest quarterly update, which combined ongoing net losses with detailed progress on apitegromab’s U.S. and EU regulatory reviews as well as expansion into new neuromuscular disease studies. See our latest analysis for Scholar Rock Holding. Scholar Rock Holding’s latest regulatory milestones and ongoing net losses have come alongside firm positive momentum, with the share price returning 18.42% over 90 days and 32.03% year to date, and a...

The recent shareholder proposal targeting Darden Restaurants (DRI) board election policies has pushed governance to the forefront ahead of the company’s September 23 annual meeting and drawn fresh attention to the stock’s recent performance metrics. See our latest analysis for Darden Restaurants. Against this governance backdrop, Darden Restaurants’ recent share price performance has stayed in focus, with a 13.9% 1 month share price return and an 18.5% year to date share price return,...

In recent months, Rogers Corporation has outlined ongoing portfolio optimization efforts, including exploring the sale of underperforming legacy businesses and emphasizing organic growth over acquisitions to enhance earnings quality and financial flexibility. This shift in focus has drawn fresh investor attention because it highlights a cleaner, more focused business mix that could reshape how the company allocates capital and manages risk. We’ll now examine how Rogers’ renewed emphasis on...

Ciena (CIEN) is back in focus after e& UAE selected the company’s optical and software platforms for a Dense Wavelength Division Multiplexing network, a contract that touches both Ciena’s technology mix and client concentration story. See our latest analysis for Ciena. The e& UAE contract follows a mixed period for Ciena’s stock, with a 1 day share price return of a 1.50% decline and a 7 day share price return of a 7.54% decline. At the same time, the year to date share price return of 62.35%...